Kiora Pharmaceuticals (KPRX) EBIT Margin (2016 - 2024)

Kiora Pharmaceuticals' (KPRX) quarterly EBIT Margin came in at 12724.44% in Q2 2024, down 15497.78% quarter-over-quarter from 82.64% in Q1 2024.

Analysis

Kiora Pharmaceuticals (KPRX) EBIT Margin (2016 - 2024) Analysis & Trends

Kiora Pharmaceuticals (KPRX) has reported EBIT Margin for 6 consecutive years, with 12724.44% the latest figure, recorded in Q2 2024.

For the quarter ending Q2 2024, EBIT Margin changed N/A year-over-year to 12724.44%; the trailing twelve-month figure through Mar 2025 stood at 55210.8% (down 5522675.0% YoY), and the FY2024 full-year result was 28.15%, changed N/A from the prior year.
EBIT Margin declined to 12724.44% in Q2 2024 per KPRX's latest filing, from 82.64% in the prior quarter.
Across five years, EBIT Margin topped out at 82.64% in Q1 2024 and bottomed at 12724.44% in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Johnson & Johnson	648.35 Bn	627.59 Bn	17.26 Bn	28.21%
2	AbbVie	447.83 Bn	441.26 Bn	12.70 Bn	37.86%
3	Merck	361.73 Bn	354.59 Bn	12.21 Bn	-3.52%
4	Novartis Ag	268.16 Bn	260.47 Bn	11.24 Bn	32.97%
5	Pfizer	156.86 Bn	145.17 Bn	10.94 Bn	28.37%
6	Sanofi	52.36 Bn	44.97 Bn	10.79 Bn	9.03%
7	Revolution Medicines	43.32 Bn	43.32 Bn	-	-
8	Incyte	25.24 Bn	20.71 Bn	1.57 Bn	41.69%
9	United Therapeutics	21.59 Bn	18.93 Bn	683.80 Mn	42.23%
10	Kiora Pharmaceuticals	15.32 Mn	15.32 Mn	-	-

Historic Data

Download Data